Orally administered branaplam does not impact neurogenesis in juvenile mice, rats, and dogs

Branaplam is a therapeutic agent currently in clinical development for the treatment of infants with type 1 spinal muscular atrophy (SMA). Since preclinical studies showed that branaplam had cell-cycle arrest effects, we sought to determine whether branaplam may affect postnatal cerebellar developme...

Descripción completa

Detalles Bibliográficos
Autores principales: Theil, Diethilde, Valdez, Reginald, Darribat, Katy, Doelemeyer, Arno, Sivasankaran, Rajeev, Hartmann, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565466/
https://www.ncbi.nlm.nih.gov/pubmed/34528068
http://dx.doi.org/10.1242/bio.058551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565466/
https://www.ncbi.nlm.nih.gov/pubmed/34528068
http://dx.doi.org/10.1242/bio.058551

Ejemplares similares